Stay updated with breaking news from Published June. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from ORION-3 open-label trial show twice-yearly* Leqvio(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C)
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
Charles Darwin suggested that “a taste for collecting beetles is some indication of future success in life."
RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who...
Welcome to Jenner & Block’s Government Contracts Legal Round‑Up, a biweekly update on important government contracts developments. This update offers brief summaries of key developments...